Single genetic assay could help physicians decide when to switch patients from Gleevec to Sutent

September 14, 2006

CHICAGO -- Researchers have found that the same gene mutation responsible for a tepid response to Gleevec (imatinib) in treatment of gastrointestinal stromal tumors (GIST), bestows benefit when a newer targeted therapy, Sutent (sunitinib), is used.

They also discovered that a different GIST tumor mutation predicts the opposite - a better response to Gleevec than to Sutent.

This means, the researchers say, that a single genetic assay could potentially help physicians decide when to switch patients from Gleevec, the first-line treatment, to therapy with Sutent, which the FDA approved for second-line use for this cancer in January 2006.

Results were presented at the first meeting on the Molecular Diagnostics in Cancer Therapeutic Development, organized by the American Association for Cancer Research.

"This is a story about personalized medicine," said the lead researcher, Michael C. Heinrich, M.D., professor of medicine at Oregon Health and Science University. "Treatment isn't one-size-fits-all anymore. We can individualize therapy based on the types of mutations found in tumor cells.

"In the case of GIST, we now understand more about how the mutational status of a patient's tumor predicts response to different targeted therapies."

Gleevec revolutionized the care of GIST, a rare cancer resistant to chemotherapy when advanced. Gleevec blocks the abnormal tyrosine kinase enzyme that plays a role in both chronic myeloid leukemia (CML) and in GIST, for which the drug was approved for use in 2001, and 2002, respectively.

But not all patients respond equally well to Gleevec, and many become resistant. Follow-up studies have found that the various mutations present on the tyrosine kinase enzyme can predict the degree of Gleevec benefit, Heinrich said. For example, 85 percent of GIST patients have a mutation in their tumor cell's c-kit gene, which encodes a tyrosine kinase receptor, and the two-thirds of those patients whose mutation occurs in exon 11 of the molecule have the longest average response to Gleevec. But these tumors often mutate again, conferring resistance to Gleevec. The 10-15 percent of patients with a mutation in exon 9 don't respond as well to the drug, but are less likely to mutate again, and those with no mutations show the least benefit, he said.

Sutent, a more potent tyrosine kinase inhibitor with a wider range of action, demonstrated a survival turnaround for Gleevec-resistant patients in recent studies, so Heinrich and his research team looked to see whether c-kit exon position also predicted response to Sutent.

They examined primary and secondary mutations in tumor samples from 74 patients, and found "a striking relationship," Heinrich said. "Patients with tumors that are wild type or have an exon 9 mutation have a longer survival when treated with Sutent than do patients with an exon 11 mutation." he said. "We are trying to figure out why that is so, but we also found that 62 percent of tumors with exon 11 mutations mutated again, and that some of these secondary mutations respond to Sutent while others don't.

"These results suggest that patients with exon 11 mutations should stay on Gleevec for a longer period of time before switching to Sutent, Heinrich said, "and that the switch to Sutent could occur earlier when treating cancers with exon 9 mutations or no mutations."
-end-
The mission of the American Association for Cancer Research is to prevent and cure cancer. Founded in 1907, AACR is the world's oldest and largest professional organization dedicated to advancing cancer research. The membership includes more than 24,000 basic, translational, and clinical researchers; health care professionals; and cancer survivors and advocates in the United States and more than 60 other countries.

AACR marshals the full spectrum of expertise from the cancer community to accelerate progress in the prevention, diagnosis and treatment of cancer through high-quality scientific and educational programs. It funds innovative, meritorious research grants. The AACR Annual Meeting attracts more than 17,000 participants who share the latest discoveries and developments in the field. Special Conferences throughout the year present novel data across a wide variety of topics in cancer research, treatment, and patient care.

AACR publishes five major peer-reviewed journals: Cancer Research; Clinical Cancer Research; Molecular Cancer Therapeutics; Molecular Cancer Research; and Cancer Epidemiology, Biomarkers & Prevention. Its most recent publication, CR, is a magazine for cancer survivors, patient advocates, their families, physicians, and scientists. It provides a forum for sharing essential, evidence-based information and perspectives on progress in cancer research, survivorship, and advocacy.

American Association for Cancer Research

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.